Published: October 01, 2026
Nearly two decades ago, a team of researchers led by cell biologist Donald Ingber at Harvard University’s Wyss Institute accomplished something extraordinary: they engineered a breathing human lung on a device smaller than a USB flash drive. By lining microfluidic channels carved into a clear polymer slab with living human cells and applying rhythmic vacuum pressure to simulate respiration, they moved beyond the static tissue cultures of the past. When exposed to pollutants and bacteria, this biomimetic hardware reacted exactly like a living human organ.
Initially, the scientific community resisted this paradigm shift. Leading journals hesitated to publish the research without parallel data from animal subjects, highlighting a long-standing reliance on mice and other animal models. Today, however, the landscape is shifting dramatically. The intersection of microfluidics, embedded sensors, and precision manufacturing is laying the foundation for a quiet revolution in drug development and toxicology: the rise of Non-Animal Methods (NAMs).
